Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype

Rosmarie Gaupp, Shulei Lei, Joseph M. Reed, Henrik Peisker, Susan Boyle-Vavra, Arnold S. Bayer, Markus Bischoff, Mathias Herrmann, Robert S. Daum, Robert Powers, Greg A Somerville

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. The success of S. aureus as a pathogen is due in part to its many virulence determinants and resistance to antimicrobials. In particular, methicillin-resistant S. aureus has emerged as a major cause of infections and led to increased use of the antibiotics vancomycin and daptomycin, which has increased the isolation of vancomycin-intermediate S. aureus and daptomycin-nonsusceptible S. aureus strains. The most common mechanism by which S. aureus acquires intermediate resistance to antibiotics is by adapting its physiology and metabolism to permit growth in the presence of these antibiotics, a process known as adaptive resistance. To better understand the physiological and metabolic changes associated with adaptive resistance, six daptomycin-susceptible and -nonsusceptible isogenic strain pairs were examined for changes in growth, competitive fitness, and metabolic alterations. Interestingly, daptomycin nonsusceptibility coincides with a slightly delayed transition to the postexponential growth phase and alterations in metabolism. Specifically, daptomycin-nonsusceptible strains have decreased tricarboxylic acid cycle activity, which correlates with increased synthesis of pyrimidines and purines and increased carbon flow to pathways associated with wall teichoic acid and peptidoglycan biosynthesis. Importantly, these data provided an opportunity to alter the daptomycin nonsusceptibility phenotype by manipulating bacterial metabolism, a first step in developing compounds that target metabolic pathways that can be used in combination with daptomycin to reduce treatment failures.

Original languageEnglish (US)
Pages (from-to)4226-4238
Number of pages13
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Daptomycin
Staphylococcus aureus
Phenotype
Vancomycin
Growth
Teichoic Acids
Anti-Bacterial Agents
Community-Acquired Infections
Pyrimidines
Purines
Citric Acid Cycle
Peptidoglycan
Methicillin-Resistant Staphylococcus aureus
Microbial Drug Resistance
Metabolic Networks and Pathways
Treatment Failure
Virulence
Carbon
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype. / Gaupp, Rosmarie; Lei, Shulei; Reed, Joseph M.; Peisker, Henrik; Boyle-Vavra, Susan; Bayer, Arnold S.; Bischoff, Markus; Herrmann, Mathias; Daum, Robert S.; Powers, Robert; Somerville, Greg A.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 7, 01.07.2015, p. 4226-4238.

Research output: Contribution to journalArticle

Gaupp, Rosmarie ; Lei, Shulei ; Reed, Joseph M. ; Peisker, Henrik ; Boyle-Vavra, Susan ; Bayer, Arnold S. ; Bischoff, Markus ; Herrmann, Mathias ; Daum, Robert S. ; Powers, Robert ; Somerville, Greg A. / Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 7. pp. 4226-4238.
@article{b069571c817c4a1fbb3397b5c495bfbf,
title = "Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype",
abstract = "Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. The success of S. aureus as a pathogen is due in part to its many virulence determinants and resistance to antimicrobials. In particular, methicillin-resistant S. aureus has emerged as a major cause of infections and led to increased use of the antibiotics vancomycin and daptomycin, which has increased the isolation of vancomycin-intermediate S. aureus and daptomycin-nonsusceptible S. aureus strains. The most common mechanism by which S. aureus acquires intermediate resistance to antibiotics is by adapting its physiology and metabolism to permit growth in the presence of these antibiotics, a process known as adaptive resistance. To better understand the physiological and metabolic changes associated with adaptive resistance, six daptomycin-susceptible and -nonsusceptible isogenic strain pairs were examined for changes in growth, competitive fitness, and metabolic alterations. Interestingly, daptomycin nonsusceptibility coincides with a slightly delayed transition to the postexponential growth phase and alterations in metabolism. Specifically, daptomycin-nonsusceptible strains have decreased tricarboxylic acid cycle activity, which correlates with increased synthesis of pyrimidines and purines and increased carbon flow to pathways associated with wall teichoic acid and peptidoglycan biosynthesis. Importantly, these data provided an opportunity to alter the daptomycin nonsusceptibility phenotype by manipulating bacterial metabolism, a first step in developing compounds that target metabolic pathways that can be used in combination with daptomycin to reduce treatment failures.",
author = "Rosmarie Gaupp and Shulei Lei and Reed, {Joseph M.} and Henrik Peisker and Susan Boyle-Vavra and Bayer, {Arnold S.} and Markus Bischoff and Mathias Herrmann and Daum, {Robert S.} and Robert Powers and Somerville, {Greg A}",
year = "2015",
month = "7",
day = "1",
doi = "10.1128/AAC.00160-15",
language = "English (US)",
volume = "59",
pages = "4226--4238",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype

AU - Gaupp, Rosmarie

AU - Lei, Shulei

AU - Reed, Joseph M.

AU - Peisker, Henrik

AU - Boyle-Vavra, Susan

AU - Bayer, Arnold S.

AU - Bischoff, Markus

AU - Herrmann, Mathias

AU - Daum, Robert S.

AU - Powers, Robert

AU - Somerville, Greg A

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. The success of S. aureus as a pathogen is due in part to its many virulence determinants and resistance to antimicrobials. In particular, methicillin-resistant S. aureus has emerged as a major cause of infections and led to increased use of the antibiotics vancomycin and daptomycin, which has increased the isolation of vancomycin-intermediate S. aureus and daptomycin-nonsusceptible S. aureus strains. The most common mechanism by which S. aureus acquires intermediate resistance to antibiotics is by adapting its physiology and metabolism to permit growth in the presence of these antibiotics, a process known as adaptive resistance. To better understand the physiological and metabolic changes associated with adaptive resistance, six daptomycin-susceptible and -nonsusceptible isogenic strain pairs were examined for changes in growth, competitive fitness, and metabolic alterations. Interestingly, daptomycin nonsusceptibility coincides with a slightly delayed transition to the postexponential growth phase and alterations in metabolism. Specifically, daptomycin-nonsusceptible strains have decreased tricarboxylic acid cycle activity, which correlates with increased synthesis of pyrimidines and purines and increased carbon flow to pathways associated with wall teichoic acid and peptidoglycan biosynthesis. Importantly, these data provided an opportunity to alter the daptomycin nonsusceptibility phenotype by manipulating bacterial metabolism, a first step in developing compounds that target metabolic pathways that can be used in combination with daptomycin to reduce treatment failures.

AB - Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. The success of S. aureus as a pathogen is due in part to its many virulence determinants and resistance to antimicrobials. In particular, methicillin-resistant S. aureus has emerged as a major cause of infections and led to increased use of the antibiotics vancomycin and daptomycin, which has increased the isolation of vancomycin-intermediate S. aureus and daptomycin-nonsusceptible S. aureus strains. The most common mechanism by which S. aureus acquires intermediate resistance to antibiotics is by adapting its physiology and metabolism to permit growth in the presence of these antibiotics, a process known as adaptive resistance. To better understand the physiological and metabolic changes associated with adaptive resistance, six daptomycin-susceptible and -nonsusceptible isogenic strain pairs were examined for changes in growth, competitive fitness, and metabolic alterations. Interestingly, daptomycin nonsusceptibility coincides with a slightly delayed transition to the postexponential growth phase and alterations in metabolism. Specifically, daptomycin-nonsusceptible strains have decreased tricarboxylic acid cycle activity, which correlates with increased synthesis of pyrimidines and purines and increased carbon flow to pathways associated with wall teichoic acid and peptidoglycan biosynthesis. Importantly, these data provided an opportunity to alter the daptomycin nonsusceptibility phenotype by manipulating bacterial metabolism, a first step in developing compounds that target metabolic pathways that can be used in combination with daptomycin to reduce treatment failures.

UR - http://www.scopus.com/inward/record.url?scp=84931274795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931274795&partnerID=8YFLogxK

U2 - 10.1128/AAC.00160-15

DO - 10.1128/AAC.00160-15

M3 - Article

VL - 59

SP - 4226

EP - 4238

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -